LENZ Therapeutics generates annual revenues reflecting its transition into a commercial-stage biopharmaceutical enterprise following regulatory approvals for its pharmaceutical eye drop portfolio, with reported revenues hovering around $21 million. Top-line financial metrics continue to scale upward as direct-to-eyecare professional marketing initiatives, product distribution networks, and commercial sales expand across domestic and international markets.